PortfoliosLab logoPortfoliosLab logo
SRPT vs. ASM
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

SRPT vs. ASM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sarepta Therapeutics, Inc. (SRPT) and Avino Silver & Gold Mines Ltd. (ASM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SRPT achieves a -24.54% return, which is significantly lower than ASM's 9.82% return. Over the past 10 years, SRPT has underperformed ASM with an annualized return of 0.42%, while ASM has yielded a comparatively higher 16.51% annualized return.


SRPT

1D
-0.06%
1M
-26.32%
YTD
-24.54%
6M
-25.64%
1Y
-58.22%
3Y*
-49.37%
5Y*
-25.96%
10Y*
0.42%

ASM

1D
-8.09%
1M
7.57%
YTD
9.82%
6M
22.00%
1Y
97.68%
3Y*
111.58%
5Y*
39.52%
10Y*
16.51%
*Multi-year figures are annualized to reflect compound growth (CAGR)

SRPT vs. ASM - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
SRPT
Sarepta Therapeutics, Inc.
-24.54%-82.30%26.09%-25.58%43.90%-47.18%32.12%18.24%96.14%102.84%
ASM
Avino Silver & Gold Mines Ltd.
9.82%604.88%68.13%-22.95%-21.01%-33.77%124.14%-4.92%-54.48%-2.19%

Correlation

The correlation between SRPT and ASM is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.12

Correlation (3Y)
Calculated over the trailing 3-year period

0.12

Correlation (5Y)
Calculated over the trailing 5-year period

0.14

Correlation (10Y)
Calculated over the trailing 10-year period

0.09

Correlation (All Time)
Calculated using the full available price history since Nov 22, 2005

0.07

Fundamentals

Market Cap

SRPT:

$1.98B

ASM:

$1.18B

EPS

SRPT:

$0.60

ASM:

$0.23

PE Ratio

SRPT:

27.06

ASM:

30.02

PS Ratio

SRPT:

0.81

ASM:

10.00

PB Ratio

SRPT:

1.32

ASM:

4.29

Total Revenue (TTM)

SRPT:

$2.18B

ASM:

$110.70M

Gross Profit (TTM)

SRPT:

$751.34M

ASM:

$59.09M

EBITDA (TTM)

SRPT:

$107.91M

ASM:

$55.20M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SRPT vs. ASM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SRPT
SRPT Risk / Return Rank: 1717
Overall Rank
SRPT Sharpe Ratio Rank: 1616
Sharpe Ratio Rank
SRPT Sortino Ratio Rank: 2222
Sortino Ratio Rank
SRPT Omega Ratio Rank: 2121
Omega Ratio Rank
SRPT Calmar Ratio Rank: 1010
Calmar Ratio Rank
SRPT Martin Ratio Rank: 1818
Martin Ratio Rank

ASM
ASM Risk / Return Rank: 7373
Overall Rank
ASM Sharpe Ratio Rank: 7676
Sharpe Ratio Rank
ASM Sortino Ratio Rank: 7272
Sortino Ratio Rank
ASM Omega Ratio Rank: 7171
Omega Ratio Rank
ASM Calmar Ratio Rank: 7373
Calmar Ratio Rank
ASM Martin Ratio Rank: 7272
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SRPT vs. ASM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and Avino Silver & Gold Mines Ltd. (ASM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SRPTASMDifference

Sharpe ratio

Return per unit of total volatility

-0.56

1.23

-1.79

Sortino ratio

Return per unit of downside risk

-0.36

1.90

-2.25

Omega ratio

Gain probability vs. loss probability

0.94

1.23

-0.29

Calmar ratio

Return relative to maximum drawdown

-0.81

1.87

-2.68

Martin ratio

Return relative to average drawdown

-1.08

4.20

-5.28

SRPT vs. ASM - Sharpe Ratio Comparison

The current SRPT Sharpe Ratio is -0.56, which is lower than the ASM Sharpe Ratio of 1.23. The chart below compares the historical Sharpe Ratios of SRPT and ASM, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


SRPTASMDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.56

1.23

-1.79

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.37

0.61

-0.98

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.01

0.24

-0.23

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.03

0.09

-0.13

Drawdowns

SRPT vs. ASM - Drawdown Comparison

The maximum SRPT drawdown since its inception was -98.17%, roughly equal to the maximum ASM drawdown of -94.10%. Use the drawdown chart below to compare losses from any high point for SRPT and ASM.


Loading charts...

Drawdown Indicators


SRPTASMDifference

Max Drawdown

Largest peak-to-trough decline

-98.17%

-94.10%

-4.07%

Max Drawdown (1Y)

Largest decline over 1 year

-72.26%

-52.40%

-19.86%

Max Drawdown (3Y)

Largest decline over 3 years

-92.72%

-52.40%

-40.32%

Max Drawdown (5Y)

Largest decline over 5 years

-92.72%

-68.51%

-24.21%

Max Drawdown (10Y)

Largest decline over 10 years

-93.33%

-90.91%

-2.42%

Current Drawdown

Current decline from peak

-90.91%

-39.32%

-51.59%

Average Drawdown

Average peak-to-trough decline

-68.14%

-63.79%

-4.35%

Ulcer Index

Depth and duration of drawdowns from previous peaks

54.00%

23.32%

+30.68%

Volatility

SRPT vs. ASM - Volatility Comparison

The current volatility for Sarepta Therapeutics, Inc. (SRPT) is 17.02%, while Avino Silver & Gold Mines Ltd. (ASM) has a volatility of 22.92%. This indicates that SRPT experiences smaller price fluctuations and is considered to be less risky than ASM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SRPTASMDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.02%

22.92%

-5.90%

Volatility (6M)

Calculated over the trailing 6-month period

52.59%

62.55%

-9.96%

Volatility (1Y)

Calculated over the trailing 1-year period

103.50%

79.93%

+23.57%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

69.81%

65.51%

+4.30%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

70.75%

69.87%

+0.88%

Dividends

SRPT vs. ASM - Dividend Comparison

Neither SRPT nor ASM has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

SRPT vs. ASM - Financials Comparison

This section allows you to compare key financial metrics between Sarepta Therapeutics, Inc. and Avino Silver & Gold Mines Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M20222023202420252026
730.80M
41.41M
(SRPT) Total Revenue
(ASM) Total Revenue
Values in USD except per share items

SRPT vs. ASM - Profitability Comparison

The chart below illustrates the profitability comparison between Sarepta Therapeutics, Inc. and Avino Silver & Gold Mines Ltd. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%202220232024202520260
61.6%
Portfolio components
SRPT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 730.80M. Therefore, the gross margin over that period was 0.0%.

ASM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Avino Silver & Gold Mines Ltd. reported a gross profit of 25.51M and revenue of 41.41M. Therefore, the gross margin over that period was 61.6%.

SRPT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported an operating income of 358.43M and revenue of 730.80M, resulting in an operating margin of 49.1%.

ASM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Avino Silver & Gold Mines Ltd. reported an operating income of 21.76M and revenue of 41.41M, resulting in an operating margin of 52.5%.

SRPT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported a net income of 330.96M and revenue of 730.80M, resulting in a net margin of 45.3%.

ASM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Avino Silver & Gold Mines Ltd. reported a net income of 15.69M and revenue of 41.41M, resulting in a net margin of 37.9%.


Frequently Asked Questions


SRPT and ASM have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ASM has higher volatility (22.92%) compared to SRPT (17.02%). In terms of maximum drawdown, SRPT dropped -98.17% vs ASM's -94.10%.

ASM currently has the higher Sharpe Ratio (1.23 vs -0.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SRPT and ASM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer